Insider trades by month
US insider trades, April 2026
The 9,432 open-market buys and sales by US company CEOs, executives and directors filed in April 2026.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Applied DigitalAPLD | Open-market sale | 04/28–04/30 | 04/30 | 25,000 sh2 trades | $33.30avg. | $832,375 | −10.7% | |
Phibro Animal HealthPAHC | Open-market sale10b5-1 plan | 04/28–04/30 | 04/30 | 21,120 sh7 trades | $53.86avg. | $1,137,619.42 | −22.0% | |
Thomas F. Lydon Jr.Director | Guggenheim Strategic Opportunities FundGOF | Open-market buy | 04/30 | 04/30 | 8,710 sh | $11.45 | $99,729.5 | No record |
PBF EnergyPBF | Open-market sale | 04/29–04/30 | 04/30 | 365,000 sh2 trades | $43.51avg. | $15,880,230 | −1.9% | |
Peter J. ArduiniPresident and CEO | GE HealthCare TechnologiesGEHC | Open-market buy | 04/30 | 04/30 | 4,169 sh | $59.93 | $249,848.17 | +1.6% |
Richard O. SchaumDirector | GentexGNTX | Open-market sale | 04/30 | 04/30 | 4,815 sh | $23.31 | $112,237.65 | −5.6% |
Frank R. JimenezGC & Corporate Secretary | GE HealthCare TechnologiesGEHC | Open-market buy | 04/30 | 04/30 | 1,750 sh | $60.45 | $105,787.5 | +1.9% |
Kiniksa Pharmaceuticals InternationalKNSA | Open-market sale10b5-1 plan | 04/28–04/30 | 04/30 | 508,339 sh6 trades | $51.96avg. | $26,415,228.13 | −100.0% | |
Archana DeskusDirector | East West BancorpEWBC | Open-market sale | 04/30 | 04/30 | 1,800 sh | $125.55 | $225,990 | −12.0% |
Avis Budget GroupCAR | Open-market sale | 04/30 | 04/30 | 9,483 sh2 trades | $182.32avg. | $1,728,900.15 | −20.0% | |
Phibro Animal HealthPAHC | Open-market sale10b5-1 plan | 04/28–04/30 | 04/30 | 21,120 sh7 trades | $53.86avg. | $1,137,619.42 | −22.0% | |
John Martin McCaffery Jr.EVP & CFO | Norwood FinancialNWFL | Open-market buy | 04/30 | 04/30 | 1,000 sh | $29.44 | $29,440 | +33.3% |
HeartflowHTFL | Open-market sale | 04/28–04/30 | 04/30 | 2,000,000 sh4 trades | $29.45avg. | $58,898,336.45 | −19.1% | |
Air A. Bastarrica Jr.Vice President, Controller | KnowlesKN | Open-market sale | 04/30 | 04/30 | 3,623 sh | $30.91 | $111,986.93 | −7.1% |
Michelle R. CassabaumDirector | Ames NationalATLO | Open-market buy | 04/30 | 04/30 | 84 sh | $28.08 | $2,358.72 | +0.9% |
Gwenn HansenChief Scientific Officer | Nurix TherapeuticsNRIX | Open-market sale | 04/30 | 04/30 | 3,214 sh | $16.65 | $53,513.1 | −2.6% |
Christine RingChief Legal Officer | Nurix TherapeuticsNRIX | Open-market sale | 04/30 | 04/30 | 3,214 sh | $16.65 | $53,513.1 | −9.2% |
Nurix TherapeuticsNRIX | Open-market sale | 04/30 | 04/30 | 2,388 sh | $16.65 | $39,760.2 | −4.4% | |
Stephen D. GriffinPresident and CEO | Anika TherapeuticsANIK | Open-market buy | 04/30 | 04/30 | 12,200 sh | $12.29 | $149,938 | +50.9% |
CleneCLNN | Open-market sale | 04/28–04/30 | 04/30 | 19,497 sh3 trades | $5.78avg. | $112,778.88 | −6.6% |
Other months
- September 20261,445
- June 202620,298
- May 202614,504
- April 20269,432
- March 202614,721
- February 202610,638
- January 20267,844
- December 202512,093
- November 202511,751
- October 202513,072
- September 202513,090
- August 202514,381
- July 20258,748
- June 202511,426
- May 202511,415
- April 20256,792
- March 202512,399
- February 202510,686
- January 20258,151
- December 202416,069
- November 202416,983
- October 20248,518
- September 202410,511
- August 202414,013
- July 202410,847
- June 202412,704
- May 202412,649
- April 20248,608
- March 202417,622
- February 202413,916
- January 20249,748
- December 202314,239
- November 202312,685
- October 20236,365
- September 20239,845
- August 202312,892
- July 20237,232
- June 202311,204
- May 202313,009
- April 20235,870
- March 202313,084
- February 202311,300
- January 20238,626